person · Reporting owner

Pizzo Philip A.

Disclosed activity across 2 companies

Tapewire entity: 123224
SEC CIK: 0001574286

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ClearPoint Neuro, Inc.MRIC · Entity 2367	Director	October 04, 2017	October 05, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ClearPoint Neuro, Inc.

Report date October 04, 2017 · Filed October 05, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Philip and Margaret Pizzo Living Trust	6,433	Reported balance After 2017-10-04 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2017-10-04 · Grant · Acquired 808 · Balance 6,433 F1: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.47 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 29, 2017.
Common StockSEC Table I · non-derivative	Direct	239	Reported balance Holding disclosure · report date 2017-10-04 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 239

Filing footnotes · ownership attribution and instrument terms

F1: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.47 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 29, 2017.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Global Blood Therapeutics, Inc.

Report date October 05, 2022 · Filed October 06, 2022

Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-05 transaction · row 1 1 source row Row 1 · 2022-10-05 · Disposition to issuer · Disposed 9,112 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-10-05 · Disposition to issuer · Disposed 3,600 · Balance 0 F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.25	Direct	Reported balance After 2022-10-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.30	Direct	Reported balance After 2022-10-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-05 · Disposition to issuer · Disposed 7,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.75	Direct	Reported balance After 2022-10-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-10-05 · Disposition to issuer · Disposed 5,247 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.09	Direct	Reported balance After 2022-10-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30	Direct	Reported balance After 2022-10-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.49	Direct	Reported balance After 2022-10-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-10-05 · Disposition to issuer · Disposed 30,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 05, 2022 Filed Oct 6, 2022 16:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	30,000	Not disclosed Strike: $46.49	Not disclosed	Disclosure SEC source: 0000899243-22-033158 · doc4.xml · derivative · entry 8 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	5,600	Not disclosed Strike: $22.30	Not disclosed	Disclosure SEC source: 0000899243-22-033158 · doc4.xml · derivative · entry 7 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,600 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	5,600	Not disclosed Strike: $37.09	Not disclosed	Disclosure SEC source: 0000899243-22-033158 · doc4.xml · derivative · entry 6 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,600 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	5,247	Not disclosed Strike: $64.75	Not disclosed	Disclosure SEC source: 0000899243-22-033158 · doc4.xml · derivative · entry 5 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,247 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	7,500	Not disclosed Strike: $56.30	Not disclosed	Disclosure SEC source: 0000899243-22-033158 · doc4.xml · derivative · entry 4 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerStock Option (Right to Buy) · Derivative	15,000	Not disclosed Strike: $42.25	Not disclosed	Disclosure SEC source: 0000899243-22-033158 · doc4.xml · derivative · entry 3 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerRestricted Stock Units · Derivative	3,600	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033158 · doc4.xml · derivative · entry 2 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,600 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerCommon Stock	9,112	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033158 · doc4.xml · nonDerivative · entry 1 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2 · price: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. Read SEC document
June 21, 2022 Filed Jun 22, 2022 18:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	1,260	$27.25	$34,337.14	Disclosure SEC source: 0000899243-22-023598 · doc4.xml · nonDerivative · entry 1 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,112 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022 to cover the Reporting Person's tax obligations in connection with the vesting of 3,600 shares of Common Stock underlying the Reporting Person's RSUs as previously reported on the Form 4 filed by the Reporting Person on June 16, 2022. F2 · price: Represents the weighted average sale price of the shares sold ranging from $26.80 to $27.69 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 14, 2022 Filed Jun 16, 2022 18:01 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	3,600	$0.00	$0.00	Disclosure SEC source: 0000899243-22-022890 · doc4.xml · derivative · entry 4 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 14, 2022 Filed Jun 16, 2022 18:01 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	5,600	$0.00 Strike: $22.30	$0.00	Disclosure SEC source: 0000899243-22-022890 · doc4.xml · derivative · entry 3 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 5,600 shares Expires 2032-06-13 F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 14, 2022 for 11 months and the remaining 1/12th on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 14, 2022 Filed Jun 16, 2022 18:01 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	3,600	$0.00	$0.00	Disclosure SEC source: 0000899243-22-022890 · doc4.xml · derivative · entry 2 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 14, 2022. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 14, 2022. Read SEC document
June 14, 2022 Filed Jun 16, 2022 18:01 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	3,600	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-022890 · doc4.xml · nonDerivative · entry 1 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 18, 2021 Filed Jun 21, 2021 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	1,065	$36.54	$38,915.10	Disclosure SEC source: 0000899243-21-024969 · doc4.xml · nonDerivative · entry 2 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,772 F2 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 7, 2021 to cover the Reporting Person's tax obligations in connection with the vesting of 3,037 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
June 17, 2021 Filed Jun 21, 2021 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	3,600	$0.00	$0.00	Disclosure SEC source: 0000899243-21-024969 · doc4.xml · derivative · entry 5 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 17, 2021 Filed Jun 21, 2021 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	5,600	$0.00 Strike: $37.09	$0.00	Disclosure SEC source: 0000899243-21-024969 · doc4.xml · derivative · entry 4 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 5,600 shares Expires 2031-06-16 F4 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2021 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 17, 2021 Filed Jun 21, 2021 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	3,037	$0.00	$0.00	Disclosure SEC source: 0000899243-21-024969 · doc4.xml · derivative · entry 3 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vested in a single installment on June 17, 2021. F3 · derivative.expiration_date: The RSUs vested in a single installment on June 17, 2021. Read SEC document
June 17, 2021 Filed Jun 21, 2021 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	3,037	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-024969 · doc4.xml · nonDerivative · entry 1 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 17, 2020 Filed Jun 19, 2020 21:22 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	3,037	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017305 · doc4.xml · derivative · entry 4 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,037 Underlying: Common Stock · 3,037 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 17, 2020 Filed Jun 19, 2020 21:22 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	5,247	$0.00 Strike: $64.75	$0.00	Disclosure SEC source: 0000899243-20-017305 · doc4.xml · derivative · entry 3 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,247 Underlying: Common Stock · 5,247 shares Expires 2030-06-16 F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2020 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 17, 2020 Filed Jun 19, 2020 21:22 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	4,800	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017305 · doc4.xml · derivative · entry 2 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document
June 17, 2020 Filed Jun 19, 2020 21:22 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	4,800	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-017305 · doc4.xml · nonDerivative · entry 1 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
December 11, 2019 Filed Dec 13, 2019 17:46 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $28.45	$0.00	Disclosure SEC source: 0000899243-19-029172 · doc4.xml · derivative · entry 6 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this option vested and became exercisable in 12 equal monthly installments, with the first installment on July 20, 2017. Read SEC document
December 11, 2019 Filed Dec 13, 2019 17:46 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $18.85	$0.00	Disclosure SEC source: 0000899243-19-029172 · doc4.xml · derivative · entry 5 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vested and became exercisable in 12 equal monthly installments, with the first installment on July 16, 2016. Read SEC document
December 11, 2019 Filed Dec 13, 2019 17:46 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	2,132	$77.25	$164,698.49	Disclosure SEC source: 0000899243-19-029172 · doc4.xml · nonDerivative · entry 4 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Represents the weighted average sale price of the shares sold from $77.12 to $77.38 per share. Read SEC document
December 11, 2019 Filed Dec 13, 2019 17:46 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	27,868	$76.52	$2,132,529.03	Disclosure SEC source: 0000899243-19-029172 · doc4.xml · nonDerivative · entry 3 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,132 F1 · price: Represents the weighted average sale price of the shares sold from $76.12 to $77.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 and 2. Read SEC document
December 11, 2019 Filed Dec 13, 2019 17:46 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	15,000	$28.45	$426,750.00	Disclosure SEC source: 0000899243-19-029172 · doc4.xml · nonDerivative · entry 2 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 11, 2019 Filed Dec 13, 2019 17:46 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	15,000	$18.85	$282,750.00	Disclosure SEC source: 0000899243-19-029172 · doc4.xml · nonDerivative · entry 1 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 18, 2019 Filed Jun 20, 2019 16:01 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	4,800	$0.00	$0.00	Disclosure SEC source: 0000899243-19-017616 · doc4.xml · derivative · entry 2 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Underlying: Common Stock · 4,800 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 18, 2019 Filed Jun 20, 2019 16:01 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $56.30	$0.00	Disclosure SEC source: 0000899243-19-017616 · doc4.xml · derivative · entry 1 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-17 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 18, 2019, for 11 months and the remaining 1/12th on the earlier of (i) June 18, 2020 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 20, 2018 Filed Jun 22, 2018 18:25 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $42.25	$0.00	Disclosure SEC source: 0000899243-18-017772 · doc4.xml · derivative · entry 1 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2018, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer. Read SEC document
October 04, 2017 Filed Oct 5, 2017 20:09 UTC	ClearPoint Neuro, Inc. MRIC · Entity 2367	GrantCommon Stock	808	$2.47	$1,995.76	Disclosure SEC source: 0001534424-17-000414 · pizzo.xml · nonDerivative · entry 1 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Philip and Margaret Pizzo Living Trust Disclosed balance after: 6,433 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.47 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 29, 2017. Read SEC document
June 20, 2017 Filed Jun 22, 2017 21:49 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $28.45	$0.00	Disclosure SEC source: 0000899243-17-016995 · doc4.xml · derivative · entry 1 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2017, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer. Read SEC document
December 30, 2016 Filed Jan 3, 2017 21:56 UTC	ClearPoint Neuro, Inc. MRIC · Entity 2367	GrantCommon Stock	2,370	$2.64	$6,256.80	Disclosure SEC source: 0001534424-17-000015 · pizzo.xml · nonDerivative · entry 1 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Philip and Margaret Pizzo Living Trust Disclosed balance after: 5,625 F1 · price: These shares were issued pursuant to the issuer's Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under such plan. The shares were issued at a price of $2.64 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 30, 2016. Read SEC document
September 30, 2016 Filed Oct 4, 2016 20:30 UTC	ClearPoint Neuro, Inc. MRIC · Entity 2367	GrantCommon Stock	864	$6.65	$5,745.60	Disclosure SEC source: 0001534424-16-001069 · pizzo.xml · nonDerivative · entry 1 Pizzo Philip A. · CIK 0001574286 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Philip and Margaret Pizzo Living Trust Disclosed balance after: 3,255 F1 · price: These shares were issued pursuant to the issuer's Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under such plan. The shares were issued at a price of $6.65 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2016. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.